Multiple conditions can be impacted by pregnancy. See 3.20, PURTSCHER RETINOPATHY; 10.10, CAVERNOUS SINUS AND ASSOCIATED SYNDROMES (MULTIPLE OCULAR MOTOR NERVE PALSIES); 10.16, IDIOPATHIC INTRACRANIAL HYPERTENSION/PSEUDOTUMOR CEREBRI; 10.27, MIGRAINE; 11.12, DIABETIC RETINOPATHY; and 11.15, CENTRAL SEROUS CHORIORETINOPATHY. Remember that medications deserve special attention during pregnancy. In 2015, the Food and Drug Administration (FDA) replaced the former pregnancy risk letter categories (A, B, C, D, X) with the updated Pregnancy and Lactation Labeling Rule (PLLR). In the old system, ophthalmic drops used regularly for examination, such as proparacaine hydrochloride 0.5% for topical anesthesia and tropicamide 0.5% or 1% and phenylephrine hydrochloride 2.5% for dilation, were considered category C drugs in pregnancy. This means that their effects are unknown, as there are no adequate and well-controlled studies in humans. Many ophthalmic drops have not yet been reclassified using the new PLLR system. Physicians should familiarize themselves with the current labeling system, refer to drug package inserts, and/or consult with the patient’s obstetrics and gynecology physician prior to use. If topical ophthalmic drops are utilized during pregnancy, patients should be advised to perform punctal occlusion with a finger for several minutes after drop instillation to decrease systemic absorption.